Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30507904 | 1.00 | PRKCI (0.31) | PRKCIBUB1 | |
| SCHEMBL7704567 | 0.83 | PRKCI (0.34) | PRKCI | |
| SCHEMBL3581102 | 0.75 | NCF1 (0.32) | BUB1 | |
| SCHEMBL15308536 | 0.75 | CCR1 (0.35) | BUB1 | |
| SCHEMBL18739049 | 0.75 | BUB1 (0.30) | BUB1 | |
| SCHEMBL16664933 | 0.75 | ADRA2A (0.31) | BUB1 | |
| SCHEMBL8482964 | 0.75 | AXL (0.31) | PRKCIBUB1 | |
| SCHEMBL25263347 | 0.73 | PARP1 (0.30) | — | |
| SCHEMBL30259052 | 0.73 | PARP1 (0.30) | — | |
| Hydrochloric Acid SCHEMBL3585467 | 0.73 | NCF1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116606298-A | Synthesis method of 2, 3-dihydro- [1,4] dioxa [2,3-b ] pyridine-8-carboxylic acid | 康化（上海）新药研发有限公司 | 2023-08-18 | — | — | CN | disclosed |
| WO-2023138674-A1 | N-HYDROXYQUINOLINE CARBOXAMIDE COMPOUND AND USE THEREOF | 默达药物（香港）有限公司 | 2023-07-27 | — | — | WO | disclosed |
| EP-4096659-A1 | SREBP INHIBITORS COMPRISING A THIOPHENE CENTRAL RING | Capulus Therapeutics, LLC (US) | 2022-12-07 | — | — | EP | disclosed |
| WO-2021154735-A1 | SREBP INHIBITORS COMPRISING A THIOPHENE CENTRAL RING | CAPULUS THERAPEUTICS, LLC (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021154735-A1 | SREBP INHIBITORS COMPRISING A THIOPHENE CENTRAL RING | CAPULUS THERAPEUTICS, LLC (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2019072978-A1 | MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF PROLIFERATION DISORDERS | Basilea Pharmaceutica International AG (CH) | 2019-04-18 | — | — | WO | disclosed |
| US-20100081650-A1 | Antimicrobial Compounds | AXTEN JEFFREY MICHAEL | 2010-04-01 | — | — | US | disclosed |
| US-7622481-B2 | Antibacterial compounds | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| EP-1537123-B1 | AMINO-SUBSTITUTED CYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS | GLAXO GROUP LTD (GB) | 2009-04-29 | — | — | EP | disclosed |
| US-20060189604-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2006-08-24 | — | — | US | disclosed |
| EP-1537123-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004002992-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189604-A1 | Compounds | ELANE, PIGS, SDHA | PRKCI 4509/4885BUB1 2381/4885 |
| US-20100081650-A1 | Antimicrobial Compounds | ELANE, NISCH, PIGS | PRKCI 4447/4885BUB1 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.